Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT326 alone and with cancer immunotherapies in advanced solid tumors
2024-517261-16-00Phase 2Authorised
- Sponsor
- BioNTech SE
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of YL202 in Nonhematologic neoplasms (2 arms), sponsored by BioNTech SE. Primary endpoints: Treatment-emergent adverse events in Part 1 monotherapy, Dose modifications and discontinuations in Part 1 monotherapy and 4 more. Planned start Dec 2025; status: authorised.
02
Drugs
YL202
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-517261-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517261-16-00.